*.*.44.54
VIP免费试用申请
登录 注册
反馈纠错 帮助中心
-

1.更多功能请前往企业版,立即体验


2.医疗器械行业政策法规查询:药智医械数据


3.掌握医院零售、 电商 三大终端市场的销售脉搏,就用 药品市场全终端分析系统 (←点击链接免费试用)


4.全面洞察药品零售数据,助力企业精准决策,把握市场增长,就用穿云众客-零售药品消费分析决策系统(←点击链接免费试用)

并且含
法规标题
并且含
正文查询
-

高级检索有“或者(or)”、“并且(and)”、“不含(not)”三种逻辑关系,各个条件之间的逻辑运算按检索条件的先后顺序进行,先得出前个逻辑关系运算结果,再用下一个逻辑关系与之运算,因此不同的检索顺序会导致不同的检索后果。


你目前无法使用部分二次筛选功能 请联系客服开通更多权限和功能!
显示  
法规标题 发布部门 发布日期 详情
Cell-culture-inactivated influenza vaccines(集中审评中人类流感灭活疫苗年度更新申报程序建议) 欧洲药品管理局(EMA) 2002-01-01 查看
Note for guidance: Field trials with veterinary vaccines(指导说明:兽医疫苗的现场试验) 欧洲药品管理局(EMA) 2001-06-01 查看
Concept paper on vaccines used for vaccination against foot and mouth disease(口蹄疫疫苗概念文件) 欧洲药品管理局(EMA) 2001-06-01 查看
Points to consider on the reduction, elimination or substitution of thiomersal in vaccines(关于减少、消除或替代疫苗中硫柳汞的几点考虑) 欧洲药品管理局(EMA) 2001-04-01 查看
Questions and Answers on Bovine Spongiform Encephalopathies (BSE) and Vaccines(关于海绵状组织脑病及疫苗的问答) 欧洲药品管理局(EMA) 2001-04-01 查看
The reduction, elimination or substitution of thiomersal in vaccines(附录I 减毒流感疫苗的变更申请) 欧洲药品管理局(EMA) 2001-04-01 查看
Draft Guidance for Industry: Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines(行业指南:人用药物和包括疫苗在内的生物制品的上市后安全性报告) 美国食品和药物管理局(FDA) 2001-03-12 查看
Public statement on the evaluation of Bovine Spongiform Encephalopathies (BSE) - risk via the use of materials of bovine origin in or during the manufacture of vaccines(关于评估牛海绵状脑病(BSE)的公开声明——在疫苗生产过程中使用牛源性材料的风险) 欧洲药品管理局(EMA) 2001-02-28 查看
Position paper on assessment of the risk of transmission of animal spongiform encephalopathy agents by master seed materials used in the production of veterinary vaccines(关于评估兽医疫苗生产中使用的主要种子材料传播动物海绵状脑病病原体的风险的立场文件) 欧洲药品管理局(EMA) 2001-02-16 查看
关于人用浓缩狂犬病疫苗销售使用截止期限的通知 国家药品监督管理局 2001-02-08 查看
Public statement on the evaluation of bovine-spongiform-encephalopathy risk via the use of materials of bovine origin in or during the manufacture of vaccines(疫苗生产过程中使用牛源性材料导致牛海绵状脑病风险评估的公开声明) 欧洲药品管理局(EMA) 2001-02-01 查看
Public Statement on the Evaluation of Bovine Spongiform Encephalopathies ( BSE ) - Risk via the Use of Materials of Bovine Origin in or during the Manufacture of Vaccines(牛海绵状脑病的公开声明-疫苗中或生产过程中使用牛源性材料的风险) 欧洲药品管理局(EMA) 2001-02-01 查看
Concept paper on the development of a committee for proprietary medicinal products (CPMP) points to consider on stability and traceability requirements for vaccine intermediates(关于专利药物委员会(CPMP)发展的概念文件,考虑疫苗中间体的稳定性和可追溯性要求) 欧洲药品管理局(EMA) 2001-01-25 查看
Development of Committee for Proprietary Medicinal Products points to consider on stability and traceability requirements for vaccine intermediates(产权药品委员会关于疫苗中间体安全性和溯源性考虑进展) 欧洲药品管理局(EMA) 2001-01-01 查看
Development of a Committee for Proprietary Medicinal Products points to consider on stability and traceability requirements for vaccine intermediates(附录I 减毒流感疫苗的变更申请) 欧洲药品管理局(EMA) 2001-01-01 查看
Guidance for Reviewers: Potency Limits for Standardized Dust Mite and Grass Allergen Vaccines: A Revised Protocol(评审指南:标准化尘螨和草过敏原疫苗的效价范围:修订后的协议) 美国食品和药物管理局(FDA) 2000-11-20 查看
Potency Limits for Standardized Dust Mite and Grass Allergen Vaccines: A Revised Protocol - Guidance for Reviewers(标准化尘螨和草过敏原疫苗的效价范围:修订后的协议-评审指南) 美国食品和药物管理局(FDA) 2000-10-20 查看
Note for guidance: Duration of protection achieved by veterinary vaccines(指导说明:兽医疫苗的保护期) 欧洲药品管理局(EMA) 2000-10-01 查看
Note for guidance: DNA vaccines non-amplifiable in eukaryotic cells for veterinary use(指南注释:兽医用真核细胞中不可扩增的DNA疫苗) 欧洲药品管理局(EMA) 2000-03-01 查看
Note for guidance: Requirements for combined veterinary vaccines(指导说明:复合兽医疫苗的要求) 欧洲药品管理局(EMA) 2000-03-01 查看
×××××
在线咨询在线咨询联系客服反馈建议APP下载

扫码下载APP

公众号

扫码关注
药智数据公众号

扫码关注
药智网公众号